Showing 1-10 of 21 grants
| Title | Institution | Researcher | Program | Duration | Total Award Amount |
|---|---|---|---|---|---|
| Engineered Nanocapsules for Targeted Drug Delivery to the β-Cell | Colorado School of Mines | Nikki Farnsworth | Cures | 01-April-2023 to 31-March-2026 | $900,000.00 |
| Anti-Serpin B13 Hu-mAb Lead Candidate Developability Assessment | Mosaic Biosciences, Inc. | Malavi Madireddi | Cures | 01-June-2025 to 01-April-2026 | $293,674.00 |
| Advanced CGM analyses for longitudinal monitoring of early-stage Type 1 Diabetes | Regents of the University of Colorado | Andrea Steck | Cures | 01-October-2024 to 30-September-2027 | $900,000.00 |
| Mechanisms of B Cell Polyreactivity in Autoimmunity: Toward Precision Immunotherapy | Regents of the University of Colorado | Elena Hsieh | Cures | 01-September-2025 to 31-August-2026 | $149,965.60 |
| Clinic-based sleep screening and intervention to improve sleep health in adolescents with type 1 diabetes | Regents of the University of Colorado | Erin Cobry | Transportfolio | 01-April-2022 to 31-March-2027 | $750,000.00 |
| Expanding Technology Success into Novel Populations: Safety and Feasibility Testing of a Fully Closed Loop System in Adolescents and Young Adults with High Baseline HbA1c Values | Regents of the University of Colorado | Gregory Forlenza | Improving Lives | 01-November-2022 to 30-June-2025 | $999,996.26 |
| Cognitive behavioral therapy to address anxiety in pre symptomatic type 1 diabetes | Regents of the University of Colorado | Holly O'Donnell | Cures | 01-July-2024 to 30-June-2027 | $600,000.00 |
| EFFICACY AND SAFETY OF ONCE WEEKLY SEMAGLUTIDE IN ADULTS WITH OBESITY AND INADEQUATELY CONTROLLED TYPE 1 DIABETES USING HYBRID CLOSED-LOOP SYSTEM | Regents of the University of Colorado | Janet Snell-Bergeon | Improving Lives | 01-November-2022 to 31-October-2026 | $2,282,771.83 |
| Effect of Montelukast on Kidney and Vascular Function in Type 1 Diabetes | Regents of the University of Colorado | Jessica Kendrick | Improving Lives | 01-October-2022 to 30-September-2026 | $899,235.00 |
| Islet autoantibody concordance and metabolic monitoring of individuals identified at risk for type 1 diabetes through population-based screening | Regents of the University of Colorado | Kimber Simmons | Cures | 01-July-2023 to 30-June-2026 | $750,000.00 |